Health · Full coverage
New Pancreatic Cancer Drug Approved by FDA Faces Cost and Accessibility Hurdles
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
Center 1Unrated 1
First reported by Ynet · 1 day ago
What happened
The FDA has approved Rasonque, a new drug for metastatic pancreatic cancer, offering extended survival but at a high cost. While accessible in Israel via personal import, official market entry and inclusion in the national health basket face significant delays and financial challenges, potentially impacting insurance coverage and patient costs.
- 01FDA approves Rasonque for metastatic pancreatic cancer, extending survival.
- 02Drug costs $40,000 monthly, posing significant financial challenges.
- 03Personal import to Israel possible, but official approval and health basket inclusion are delayed.
- 04High costs may lead to increased insurance premiums or restricted coverage.
- 05Company stock surged, with significant market potential estimated.
- 06Doctors hope for broader application in other RAS-mutated cancers.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
In this story
People
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
FDA Approves Breakthrough Drug for Advanced Pancreatic Cancer Extending Survival4 days agoIchilov Launches World-First Clinical Trial for Innovative Pancreatic Cancer TreatmentJul 30, 2026FDA Approves Revtorpyk to Cut Advanced Breast Cancer Progression Risk by 76%Jul 15, 2026CT Review Missed Early Pancreatic Cancer, Patient Dies 18 Months LaterJun 18, 2026New Targeted Therapies Revolutionize Breast Cancer Treatment and Survival in IsraelJul 5, 2026Israeli Family Battles to Secure 14 Million Shekel Drug for Rare Genetic DiseaseJun 28, 2026
